How is Blinatumomab (Intravenous Route) dosed?
The dosage for treating B-cell precursor acute lymphoblastic leukemia (ALL) in remission with minimal residual disease (MRD) or relapsed ALL is usually 9 mcg per day for the first 7 days, then 28 mcg per day for the next 3 weeks, and 46 mcg per day for the remaining 4 weeks. The dosage for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) is 9 mcg per day for the first 7 days, then 28 mcg per day for the next 3 weeks, and 46 mcg per day for the remaining 4 weeks. These dosages are a general guideline and may vary based on the patient's response to treatment and other factors. Follow your doctor's instructions carefully and consult your healthcare provider before adjusting your dose.
What is the dosage form of Blinatumomab (Intravenous Route)?
The available dosage form of blinatumomab (Intravenous Route) is Powder for Solution.
How is Blinatumomab (Intravenous Route) administered?
Blinatumomab (Intravenous Route) is administered by a nurse or other trained health professional in a medical facility. It is given through a needle placed into one of the veins. The medicine is typically given every day for 4 weeks (28 days) followed by a 2-week treatment-free interval. This is one treatment cycle. Additional treatment cycles will be determined by the doctor after the 2-week break.
What are common precautions when taking Blinatumomab (Intravenous Route)?
When taking blinatumomab (Intravenous Route), there are several precautions to keep in mind:
- Inform your doctor if you have a history of allergies or hypersensitivity to blinatumomab or any of its components, as this medication may cause an allergic reaction.
- Blinatumomab may cause infusion reactions, including fever, chills, and difficulty breathing. These reactions can occur during the infusion or within 24 hours after the infusion. Inform your healthcare provider if you experience any of these symptoms.
- This medication may weaken the immune system, increasing the risk of infections. Inform your doctor if you experience signs of an infection, such as fever, chills, or persistent cough.
- Blinatumomab may cause serious complications during pregnancy or breastfeeding. Consult your doctor before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.
- Inform your doctor about any other medications you are taking, as blinatumomab may interact with other drugs, including prescription and over-the-counter medications, vitamins, and herbal supplements.
- This medication may cause dizziness, confusion, or decreased alertness. Avoid driving or operating machinery until you know how blinatumomab affects you.
- Blinatumomab may increase the risk of bleeding. Inform your doctor if you experience any unusual bruising or bleeding, such as nosebleeds, bleeding gums, or black, tarry stools.
Follow your healthcare provider's instructions carefully while using blinatumomab and report any side effects or concerns promptly.